Compare CRSP & THG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | THG |
|---|---|---|
| Founded | 2013 | 1852 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 6.0B |
| IPO Year | 2016 | 1995 |
| Metric | CRSP | THG |
|---|---|---|
| Price | $50.24 | $174.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 6 |
| Target Price | $71.95 | ★ $196.67 |
| AVG Volume (30 Days) | ★ 1.8M | 433.6K |
| Earning Date | 02-11-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | N/A | ★ 58.62 |
| EPS | N/A | ★ 18.56 |
| Revenue | $38,337,000.00 | ★ $6,594,400,000.00 |
| Revenue This Year | N/A | $4.23 |
| Revenue Next Year | $1,376.73 | $5.18 |
| P/E Ratio | ★ N/A | $9.38 |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $30.04 | $147.76 |
| 52 Week High | $78.48 | $188.18 |
| Indicator | CRSP | THG |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 48.59 |
| Support Level | $49.10 | $171.10 |
| Resistance Level | $53.00 | $174.11 |
| Average True Range (ATR) | 3.12 | 3.21 |
| MACD | -0.48 | 0.73 |
| Stochastic Oscillator | 12.40 | 44.86 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.